HL Financial Services LLC raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.0% during the second quarter, Holdings Channel reports. The firm owned 9,809 shares of the medical research company’s stock after buying an additional 4 shares during the period. HL Financial Services LLC’s holdings in Edwards Lifesciences Corporation were worth $1,160,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in EW. Quadrant Capital Group LLC increased its position in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the period. YorkBridge Wealth Partners LLC purchased a new position in Edwards Lifesciences Corporation during the first quarter valued at about $110,000. NEXT Financial Group Inc increased its position in Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares during the period. Cornerstone Advisors Inc. increased its position in Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares during the period. Finally, Alexandria Capital LLC increased its position in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the period. 84.15% of the stock is owned by institutional investors.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 114.13 on Friday. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The firm has a 50-day moving average price of $117.06 and a 200 day moving average price of $105.21. The stock has a market cap of $24.10 billion, a PE ratio of 34.62 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.76 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/edwards-lifesciences-corporation-nyseew-position-increased-by-hl-financial-services-llc.html.

Several research firms have recently issued reports on EW. BidaskClub downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 price target on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a research note on Thursday, June 1st. Goldman Sachs Group, Inc. (The) began coverage on Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They set a “conviction-buy” rating and a $138.00 price target for the company. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $135.00 price target (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $121.13.

In related news, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Patrick B. Verguet sold 11,500 shares of the stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $111.64, for a total value of $1,283,860.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 183,412 shares of company stock valued at $21,176,230. Company insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.